SLC5A2 and type 1 diabetes mellitus: Except for 5mg dapagliflozin,10mg empagliflozin,200mg sotagliflozin and 400mg sotagliflozin, no risk of DKA was observed with SGLT2 inhibitors as an adjunct to insulin in the treatment of T1DM compared to insulin.